Etoposide Completed Phase 2 Trials for Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01969435Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
NCT03794167BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma
NCT01097057Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT03792815Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
NCT00504751Phase II Study of VIPER Chemotherapy in Rel/Ref DLBCL
NCT00336583Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
NCT00262210A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
NCT00151281Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
NCT00193505Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma